The pharmaceutical industry offers a wide range of medications, including high-cost brand-name drugs and more affordable generics. This report analyzes the equivalency in efficacy between Indian WHO-certified generic drugs and their branded counterparts, highlighting differences in inactive ingredients and the economic impact on healthcare. Despite misconceptions, generics contain the same active ingredients and adhere to international quality standards, offering a cost-effective alternative without compromising safety. The lower cost of Indian generics makes essential medications more accessible, particularly in low- and middle-income countries, driving down healthcare costs and expanding access to necessary treatments.